TR200101539T2 - Serum glukoz ve trigliserid seviyelerini düşürme yöntemleri. - Google Patents
Serum glukoz ve trigliserid seviyelerini düşürme yöntemleri.Info
- Publication number
- TR200101539T2 TR200101539T2 TR2001/01539T TR200101539T TR200101539T2 TR 200101539 T2 TR200101539 T2 TR 200101539T2 TR 2001/01539 T TR2001/01539 T TR 2001/01539T TR 200101539 T TR200101539 T TR 200101539T TR 200101539 T2 TR200101539 T2 TR 200101539T2
- Authority
- TR
- Turkey
- Prior art keywords
- methods
- triglyceride levels
- serum glucose
- lower serum
- disclosed
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Açiklananlar, serum glukoz ve trigliserit düzeylerinin düsürülmesi ve anjiyojenezin inhibe edilmesi için yöntemler olup, yöntemler ikame edilmis indolalkonoik asitlerin, bu tip tedaviye gereksinimi olan hastalara tatbik edilmesini kapsar.Ayni zamanda açiklananlar, anjiyojenez, hiperglisemi, hiperlipidemi ve diabetes mellitus'tan kaynaklanan kronik komplikasyonlarin tedavisinde kullanisli olan bu tip bilesiklerdir. Ayni zamanda açiklananlar, bilesikleri içeren farmosötik bilesimlerdir.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11039598P | 1998-12-01 | 1998-12-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
TR200101539T2 true TR200101539T2 (tr) | 2001-12-21 |
Family
ID=22332786
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2001/01539T TR200101539T2 (tr) | 1998-12-01 | 1999-12-01 | Serum glukoz ve trigliserid seviyelerini düşürme yöntemleri. |
Country Status (30)
Country | Link |
---|---|
US (5) | US6555568B1 (tr) |
EP (1) | EP1135124B1 (tr) |
JP (1) | JP2002531398A (tr) |
KR (1) | KR20010086075A (tr) |
CN (1) | CN1368883A (tr) |
AP (1) | AP2001002146A0 (tr) |
AT (1) | ATE265210T1 (tr) |
AU (1) | AU770925B2 (tr) |
BG (1) | BG105531A (tr) |
BR (1) | BR9915882A (tr) |
CA (1) | CA2385845A1 (tr) |
CZ (1) | CZ20011864A3 (tr) |
DE (1) | DE69916881T2 (tr) |
DZ (1) | DZ2953A1 (tr) |
EE (1) | EE200100296A (tr) |
HK (1) | HK1046372A1 (tr) |
HU (1) | HUP0104953A3 (tr) |
ID (1) | ID30037A (tr) |
IL (1) | IL143247A0 (tr) |
MX (1) | MXPA02003118A (tr) |
NO (1) | NO20012690L (tr) |
OA (1) | OA12035A (tr) |
PL (1) | PL349016A1 (tr) |
SK (1) | SK7352001A3 (tr) |
TN (1) | TNSN99224A1 (tr) |
TR (1) | TR200101539T2 (tr) |
TW (1) | TW584560B (tr) |
WO (1) | WO2000032180A2 (tr) |
YU (1) | YU40101A (tr) |
ZA (1) | ZA200104126B (tr) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE269861T1 (de) * | 1998-03-31 | 2004-07-15 | Inst For Pharm Discovery Inc | Substituierte indolalkansäure |
TNSN99224A1 (fr) * | 1998-12-01 | 2005-11-10 | Inst For Pharm Discovery Inc | Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique |
US6521659B2 (en) * | 2000-03-02 | 2003-02-18 | Institute For Pharmaceutical Discovery, Llc | Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor |
AU2001259668A1 (en) * | 2000-05-09 | 2001-11-20 | The Institute For Pharmaceutical Discovery Llc | Methods for testing compounds useful for treating diabetic complications |
TWI224101B (en) | 2001-06-20 | 2004-11-21 | Wyeth Corp | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) |
WO2003000253A1 (en) | 2001-06-20 | 2003-01-03 | Wyeth | Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
CA2509191A1 (en) | 2002-12-10 | 2004-06-24 | Wyeth | Aryl, aryloxy, and alkyloxy substituted 1h-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
WO2004052853A2 (en) | 2002-12-10 | 2004-06-24 | Wyeth | Substituted 3-alkyl and 3-arylalkyl 1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
MXPA05006287A (es) | 2002-12-10 | 2005-09-08 | Wyeth Corp | Derivados de acido indoloxo-acetilaminoacetico sustituidos como inhibidores del inhibidor del activador de plasminogeno 1 (pai-1). |
CN1726190A (zh) | 2002-12-10 | 2006-01-25 | 惠氏公司 | 作为纤溶酶原激活物抑制剂-1(pai-1)的抑制剂的取代3-羰基-1h-吲哚-1-基乙酸衍生物 |
UA80453C2 (en) | 2002-12-10 | 2007-09-25 | Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1) | |
EP1620088A4 (en) * | 2003-04-28 | 2007-08-29 | Bayer Pharmaceuticals Corp | ACETIC INDOLE ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS |
US7342039B2 (en) | 2003-09-25 | 2008-03-11 | Wyeth | Substituted indole oximes |
US7351726B2 (en) | 2003-09-25 | 2008-04-01 | Wyeth | Substituted oxadiazolidinediones |
US7442805B2 (en) | 2003-09-25 | 2008-10-28 | Wyeth | Substituted sulfonamide-indoles |
US7446201B2 (en) | 2003-09-25 | 2008-11-04 | Wyeth | Substituted heteroaryl benzofuran acids |
US7141592B2 (en) | 2003-09-25 | 2006-11-28 | Wyeth | Substituted oxadiazolidinediones |
US7332521B2 (en) | 2003-09-25 | 2008-02-19 | Wyeth | Substituted indoles |
US7265148B2 (en) | 2003-09-25 | 2007-09-04 | Wyeth | Substituted pyrrole-indoles |
US7268159B2 (en) | 2003-09-25 | 2007-09-11 | Wyeth | Substituted indoles |
US7411083B2 (en) | 2003-09-25 | 2008-08-12 | Wyeth | Substituted acetic acid derivatives |
US7582773B2 (en) | 2003-09-25 | 2009-09-01 | Wyeth | Substituted phenyl indoles |
US7163954B2 (en) | 2003-09-25 | 2007-01-16 | Wyeth | Substituted naphthyl benzothiophene acids |
GB0324763D0 (en) * | 2003-10-23 | 2003-11-26 | Oxagen Ltd | Use of compounds in therapy |
JP4880591B2 (ja) | 2004-06-04 | 2012-02-22 | テバ ファーマシューティカル インダストリーズ リミティド | イルベサルタンを含む医薬組成物 |
RU2007106868A (ru) | 2004-08-23 | 2008-09-27 | Вайет (Us) | Оксазол-нафтиловые кислоты и их применение в качестве модуляторов ингибитора активатора плазминогена-1 (pai) для лечения тромбоза и сердечно-сосудистых заболеваний |
US20060135540A1 (en) * | 2004-11-30 | 2006-06-22 | Jack Lin | PPAR active compounds |
US7531568B2 (en) * | 2004-11-30 | 2009-05-12 | Plexxikon, Inc. | PPAR active compounds |
EP1919866A2 (en) | 2005-08-17 | 2008-05-14 | Wyeth a Corporation of the State of Delaware | Substituted indoles and use thereof |
BRPI0615929A2 (pt) * | 2005-09-07 | 2011-05-31 | Plexxikon Inc | compostos ativos de ppar, composição, kit e uso dos mesmos |
KR20090042808A (ko) | 2006-07-22 | 2009-04-30 | 옥사겐 리미티드 | 씨알티에이치2 길항제 활성을 갖는 화합물 |
PE20090159A1 (es) * | 2007-03-08 | 2009-02-21 | Plexxikon Inc | COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs |
US7750027B2 (en) * | 2008-01-18 | 2010-07-06 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
CN101932571B (zh) | 2008-01-18 | 2014-04-23 | 奥克萨根有限公司 | 具有crth2拮抗活性的化合物 |
EP2265581A1 (en) | 2008-01-22 | 2010-12-29 | Oxagen Limited | Compounds having crth2 antagonist activity |
EP2240444A1 (en) | 2008-01-22 | 2010-10-20 | Oxagen Limited | Compounds having crth2 antagonist activity |
EP2424521A4 (en) | 2009-04-29 | 2015-03-04 | Amarin Pharmaceuticals Ie Ltd | PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND CARDIOVASCULAR AGENT AND METHODS OF USE |
US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
GB201322273D0 (en) | 2013-12-17 | 2014-01-29 | Atopix Therapeutics Ltd | Process |
GB201407807D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
GB201407820D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3557142A (en) | 1968-02-20 | 1971-01-19 | Sterling Drug Inc | 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters |
IE47592B1 (en) | 1977-12-29 | 1984-05-02 | Ici Ltd | Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture |
JPS55167282A (en) | 1979-06-12 | 1980-12-26 | Fujisawa Pharmaceut Co Ltd | Piperazine derivative or its salt and its preparation |
US4283539A (en) | 1979-12-18 | 1981-08-11 | Pfizer Inc. | Isoquinoline acetic acids |
US4363912A (en) * | 1980-12-15 | 1982-12-14 | Pfizer Inc. | Indole thromboxane synthetase inhibitors |
US4442118A (en) * | 1981-07-23 | 1984-04-10 | Ayerst, Mckenna & Harrison, Inc. | Aldose reductase inhibition by 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid |
GB8607294D0 (en) | 1985-04-17 | 1986-04-30 | Ici America Inc | Heterocyclic amide derivatives |
US4939140A (en) | 1985-11-07 | 1990-07-03 | Pfizer Inc. | Heterocyclic oxophthalazinyl acetic acids |
ES2032749T3 (es) | 1985-11-07 | 1993-03-01 | Pfizer Inc. | Acidos oxoftalazinil-aceticos heterociclicos. |
US4960785A (en) | 1988-12-16 | 1990-10-02 | Pfizer Inc. | Indolinone derivatives |
WO1993012786A1 (en) | 1986-07-10 | 1993-07-08 | Howard Harry R Jr | Indolinone derivatives |
US4868301A (en) | 1987-06-09 | 1989-09-19 | Pfizer Inc. | Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains |
US5064852A (en) * | 1988-12-16 | 1991-11-12 | Pfizer Inc. | Indolinone derivatives |
US4996204A (en) | 1989-05-11 | 1991-02-26 | Pfizer Inc. | Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors |
FR2647676A1 (fr) | 1989-06-05 | 1990-12-07 | Union Pharma Scient Appl | Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase |
GB8916774D0 (en) * | 1989-07-21 | 1989-09-06 | Bayer Ag | New indole derivatives,a process for their preparation and their use in medicaments |
WO1991009019A1 (en) | 1989-12-15 | 1991-06-27 | Pfizer Inc. | Substituted oxophthalazinyl acetic acids and analogs thereof |
US5312829A (en) * | 1990-05-21 | 1994-05-17 | Fujisawa Pharmaceutical Co., Ltd. | Indole derivatives |
US5236945A (en) | 1990-06-11 | 1993-08-17 | Pfizer Inc. | 1H-indazole-3-acetic acids as aldose reductase inhibitors |
US5116753A (en) * | 1991-07-30 | 1992-05-26 | The Salk Institute For Biological Studies | Maintenance of pancreatic islets |
GB9122590D0 (en) | 1991-10-24 | 1991-12-04 | Lilly Industries Ltd | Pharmaceutical compounds |
JP3195455B2 (ja) | 1993-01-06 | 2001-08-06 | ウェルファイド株式会社 | キノリン−3−酢酸誘導体、その製造法と用途 |
US5391551A (en) | 1993-05-10 | 1995-02-21 | Pfizer Inc. | Method of lowering blood lipid levels |
AU7634694A (en) | 1993-08-20 | 1995-03-21 | University Of Medicine And Dentistry Of New Jersey | Bridged polycationic polymer-oligonucleotide conjugates and methods for preparing same |
GB9317764D0 (en) * | 1993-08-26 | 1993-10-13 | Pfizer Ltd | Therapeutic compound |
US5641800A (en) | 1994-07-21 | 1997-06-24 | Eli Lilly And Company | 1H-indole-1-functional sPLA2 inhibitors |
TW401301B (en) * | 1994-10-07 | 2000-08-11 | Takeda Chemical Industries Ltd | Antihypertriglyceridemic composition |
US5700819A (en) | 1994-11-29 | 1997-12-23 | Grelan Pharmaceutical Co., Ltd. | 2-substituted benzothiazole derivatives and prophylactic and therapeutic agents for the treatment of diabetic complications |
IL117208A0 (en) * | 1995-02-23 | 1996-06-18 | Nissan Chemical Ind Ltd | Indole type thiazolidines |
JPH09165371A (ja) | 1995-10-09 | 1997-06-24 | Sankyo Co Ltd | 複素環化合物を含有する医薬 |
ATE269861T1 (de) * | 1998-03-31 | 2004-07-15 | Inst For Pharm Discovery Inc | Substituierte indolalkansäure |
TNSN99224A1 (fr) * | 1998-12-01 | 2005-11-10 | Inst For Pharm Discovery Inc | Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique |
US6521659B2 (en) * | 2000-03-02 | 2003-02-18 | Institute For Pharmaceutical Discovery, Llc | Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor |
-
1999
- 1999-11-29 TN TNTNSN99224A patent/TNSN99224A1/fr unknown
- 1999-12-01 DE DE69916881T patent/DE69916881T2/de not_active Expired - Lifetime
- 1999-12-01 AT AT99965955T patent/ATE265210T1/de not_active IP Right Cessation
- 1999-12-01 HU HU0104953A patent/HUP0104953A3/hu unknown
- 1999-12-01 EP EP99965955A patent/EP1135124B1/en not_active Expired - Lifetime
- 1999-12-01 TR TR2001/01539T patent/TR200101539T2/tr unknown
- 1999-12-01 PL PL99349016A patent/PL349016A1/xx not_active Application Discontinuation
- 1999-12-01 EE EEP200100296A patent/EE200100296A/xx unknown
- 1999-12-01 AP APAP/P/2001/002146A patent/AP2001002146A0/en unknown
- 1999-12-01 IL IL14324799A patent/IL143247A0/xx unknown
- 1999-12-01 WO PCT/US1999/028483 patent/WO2000032180A2/en not_active Application Discontinuation
- 1999-12-01 MX MXPA02003118A patent/MXPA02003118A/es not_active IP Right Cessation
- 1999-12-01 BR BR9915882-5A patent/BR9915882A/pt not_active IP Right Cessation
- 1999-12-01 CZ CZ20011864A patent/CZ20011864A3/cs unknown
- 1999-12-01 ID IDW00200101404A patent/ID30037A/id unknown
- 1999-12-01 JP JP2000584876A patent/JP2002531398A/ja active Pending
- 1999-12-01 CN CN99814023A patent/CN1368883A/zh active Pending
- 1999-12-01 YU YU40101A patent/YU40101A/sh unknown
- 1999-12-01 CA CA002385845A patent/CA2385845A1/en not_active Abandoned
- 1999-12-01 DZ DZ990253A patent/DZ2953A1/xx active
- 1999-12-01 OA OA00100134A patent/OA12035A/en unknown
- 1999-12-01 AU AU21616/00A patent/AU770925B2/en not_active Ceased
- 1999-12-01 KR KR1020017006865A patent/KR20010086075A/ko not_active Application Discontinuation
- 1999-12-01 SK SK735-2001A patent/SK7352001A3/sk unknown
- 1999-12-01 US US09/452,252 patent/US6555568B1/en not_active Expired - Fee Related
-
2000
- 2000-02-01 TW TW088120912A patent/TW584560B/zh active
-
2001
- 2001-05-21 ZA ZA200104126A patent/ZA200104126B/en unknown
- 2001-05-22 BG BG105531A patent/BG105531A/xx unknown
- 2001-05-31 NO NO20012690A patent/NO20012690L/no not_active Application Discontinuation
-
2002
- 2002-11-02 HK HK02107989.6A patent/HK1046372A1/zh unknown
-
2003
- 2003-03-26 US US10/397,140 patent/US6964980B2/en not_active Expired - Fee Related
-
2005
- 2005-11-15 US US11/274,583 patent/US20060074114A1/en not_active Abandoned
-
2010
- 2010-08-30 US US12/871,304 patent/US20100324105A1/en not_active Abandoned
-
2011
- 2011-11-22 US US13/302,906 patent/US20120065203A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TR200101539T2 (tr) | Serum glukoz ve trigliserid seviyelerini düşürme yöntemleri. | |
AP2000001929A0 (en) | Substituted indolealkanoic acids. | |
DE69940769D1 (de) | Orale flüssige zusammensetzungen | |
BR0007820A (pt) | Formulações agonistas de exendina e métodos deadministração das mesmas | |
NO20006630D0 (no) | Farmasöytisk sammensetning for behandlingen av diabetes | |
ATE219363T1 (de) | Lösliche prodrugs von paclitaxel | |
PT896533E (pt) | Pentafluorobenzenosulfonamidas e analogos | |
DE69735442D1 (de) | Antidiabetische mittel | |
TR200003159T2 (tr) | Antipicornaviral bileşikler, hazırlanışları ve kullanımları | |
YU72594A (sh) | Vodeni rastvor inkluzionih kompleksa benzotiofen jedinjenja sa vodorastvornim ciklodekstrinima, njegove farmaceutske formulacije i postupci za dobijanje | |
KR870700599A (ko) | 카르복실산유도체, 그의 제조방법, 이화합물을 함유한 약제조성물 및 그의 용도 | |
NZ516290A (en) | Substituted phenoxyacetic acids | |
GR3034821T3 (en) | New 6-hydroxy and 6-oxo-anstro-stane derivatives active on the cardiovascular system and pharmaceutical compositions containing same | |
TR199800521T1 (tr) | Seçimli beta3 adrenerjik agonistler. | |
DE60230155D1 (de) | Verwendung von verzweigtkettigen fettsäuren und ihrer derivate zur schmerzbehandlung | |
NO20002408L (no) | 5-HT1F antagonister | |
ATE240100T1 (de) | Verwendung von fc101 als hemmstoff der angiogenese zur behandlung von krebs und anderen angiogenen krankheiten | |
Rao et al. | Bioflavonoid-mediated stabilization of collagen in adjuvant-induced arthritis | |
BG103674A (en) | Polymorphous form of zopolrestatmonohydrate | |
WO2001051489A3 (en) | Methods for lowering uric acid levels | |
WO2000054760A3 (en) | Bicyclo (3.3.1) nonenes useful for the treatment of diabetes and hypertriglyceridemia | |
ATE194498T1 (de) | Wasserfreies mittel auf lactulosebasis | |
TR200202109T2 (tr) | 5-[{6-(2-Flüorobenzil)oksi-2-naftil}metil]-2,4-tiyazolidin dion kristalleri | |
MY138338A (en) | Substituted indolealkanoic acids | |
NO996311L (no) | Loeselige forlegemidler av paklitaksel |